eb_Geir-Christian-Melen.jpg

Zelluna Immunotherapy has announced the appointment of Geir Christian Melen as chief financial officer (CFO).

Steven Docksey

Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.

Image: Exscientia

Exscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).

Albert Bourla. Picture: Pfizer Inc.

Pfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors.

eb_Guillem_Laporta_small.jpg

Ysios Capital, a biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal.

Vanessa King, Virion President & CEO (Photo: Business Wire)

Virion Biotherapeutics announced the appointments of Vanessa King, PhD, as President & Chief Executive Officer this week.

carlbjartmar.jpg

Ascelia Pharma announced on Friday Spetember 14 that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.

Bild: Torbjørn Furuseth

Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter

Johanna Ivaska

Johanna Ivaska, Academy Professor of Biochemistry has been appointed Head & Vice President of Oncology Research in Orion Corporation as of 1 October 2018.  Ivaska joins Orion from the University of Turku and will continue working also there with her internationally recognised research team.

Nessan Birmingham. Picture: Intellia Therapeutics

F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.